NASDAQ:ANAB

AnaptysBio Competitors

$21.51
+1.00 (+4.88 %)
(As of 04/14/2021 12:42 PM ET)
Add
Compare
Today's Range
$20.62
Now: $21.51
$21.60
50-Day Range
$19.00
MA: $23.21
$29.47
52-Week Range
$13.92
Now: $21.51
$35.85
Volume10,297 shs
Average Volume540,938 shs
Market Capitalization$588.64 million
P/E RatioN/A
Dividend YieldN/A
Beta0.15

Competitors

AnaptysBio (NASDAQ:ANAB) Vs. PBH, DRNA, AMRN, RVNC, AXSM, and MCRB

Should you be buying ANAB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to AnaptysBio, including Prestige Consumer Healthcare (PBH), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Revance Therapeutics (RVNC), Axsome Therapeutics (AXSM), and Seres Therapeutics (MCRB).

AnaptysBio (NASDAQ:ANAB) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for AnaptysBio and Prestige Consumer Healthcare, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AnaptysBio13302.29
Prestige Consumer Healthcare04302.43

AnaptysBio currently has a consensus price target of $30.2857, indicating a potential upside of 41.59%. Prestige Consumer Healthcare has a consensus price target of $87.60, indicating a potential upside of 98.37%. Given Prestige Consumer Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than AnaptysBio.

Earnings & Valuation

This table compares AnaptysBio and Prestige Consumer Healthcare's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnaptysBio$8 million73.58$-97,340,000.00($3.60)-5.98
Prestige Consumer Healthcare$963.01 million2.29$142.28 million$2.9614.92

Prestige Consumer Healthcare has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

AnaptysBio has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Profitability

This table compares AnaptysBio and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AnaptysBioN/A-19.09%-17.94%
Prestige Consumer Healthcare17.03%13.76%4.80%

Summary

Prestige Consumer Healthcare beats AnaptysBio on 10 of the 11 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for Dicerna Pharmaceuticals and AnaptysBio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dicerna Pharmaceuticals00603.00
AnaptysBio13302.29

Dicerna Pharmaceuticals presently has a consensus price target of $37.6667, indicating a potential upside of 34.96%. AnaptysBio has a consensus price target of $30.2857, indicating a potential upside of 41.59%. Given AnaptysBio's higher probable upside, analysts clearly believe AnaptysBio is more favorable than Dicerna Pharmaceuticals.

Profitability

This table compares Dicerna Pharmaceuticals and AnaptysBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%
AnaptysBioN/A-19.09%-17.94%

Institutional and Insider Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by insiders. Comparatively, 13.0% of AnaptysBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Dicerna Pharmaceuticals and AnaptysBio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dicerna Pharmaceuticals$23.90 million89.45$-120,460,000.00($1.76)-15.91
AnaptysBio$8 million73.58$-97,340,000.00($3.60)-5.98

AnaptysBio has lower revenue, but higher earnings than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Dicerna Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.

Summary

Dicerna Pharmaceuticals beats AnaptysBio on 8 of the 14 factors compared between the two stocks.

AnaptysBio (NASDAQ:ANAB) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for AnaptysBio and Amarin, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AnaptysBio13302.29
Amarin03802.73

AnaptysBio presently has a consensus target price of $30.2857, indicating a potential upside of 41.59%. Amarin has a consensus target price of $11.1818, indicating a potential upside of 110.98%. Given Amarin's stronger consensus rating and higher possible upside, analysts clearly believe Amarin is more favorable than AnaptysBio.

Profitability

This table compares AnaptysBio and Amarin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AnaptysBioN/A-19.09%-17.94%
Amarin-2.69%-2.70%-1.72%

Insider & Institutional Ownership

37.8% of Amarin shares are owned by institutional investors. 13.0% of AnaptysBio shares are owned by company insiders. Comparatively, 2.8% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares AnaptysBio and Amarin's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnaptysBio$8 million73.58$-97,340,000.00($3.60)-5.98
Amarin$429.76 million4.80$-22,650,000.00($0.07)-74.86

Amarin has higher revenue and earnings than AnaptysBio. Amarin is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

AnaptysBio has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500. Comparatively, Amarin has a beta of 2.58, suggesting that its stock price is 158% more volatile than the S&P 500.

Summary

Amarin beats AnaptysBio on 10 of the 14 factors compared between the two stocks.

AnaptysBio (NASDAQ:ANAB) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for AnaptysBio and Revance Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AnaptysBio13302.29
Revance Therapeutics00503.00

AnaptysBio presently has a consensus target price of $30.2857, indicating a potential upside of 41.59%. Revance Therapeutics has a consensus target price of $36.40, indicating a potential upside of 26.87%. Given AnaptysBio's higher possible upside, equities analysts clearly believe AnaptysBio is more favorable than Revance Therapeutics.

Profitability

This table compares AnaptysBio and Revance Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AnaptysBioN/A-19.09%-17.94%
Revance Therapeutics-5,818.87%-85.72%-44.85%

Insider & Institutional Ownership

74.4% of Revance Therapeutics shares are owned by institutional investors. 13.0% of AnaptysBio shares are owned by company insiders. Comparatively, 4.8% of Revance Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares AnaptysBio and Revance Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnaptysBio$8 million73.58$-97,340,000.00($3.60)-5.98
Revance Therapeutics$410,000.005,003.77$-159,430,000.00($3.67)-7.83

AnaptysBio has higher revenue and earnings than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

AnaptysBio has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

Summary

AnaptysBio beats Revance Therapeutics on 8 of the 14 factors compared between the two stocks.

AnaptysBio (NASDAQ:ANAB) and Axsome Therapeutics (NASDAQ:AXSM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Insider and Institutional Ownership

63.6% of Axsome Therapeutics shares are owned by institutional investors. 13.0% of AnaptysBio shares are owned by company insiders. Comparatively, 26.0% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for AnaptysBio and Axsome Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AnaptysBio13302.29
Axsome Therapeutics101102.83

AnaptysBio currently has a consensus target price of $30.2857, indicating a potential upside of 41.59%. Axsome Therapeutics has a consensus target price of $146.90, indicating a potential upside of 167.97%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than AnaptysBio.

Profitability

This table compares AnaptysBio and Axsome Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AnaptysBioN/A-19.09%-17.94%
Axsome TherapeuticsN/A-62.33%-47.87%

Volatility & Risk

AnaptysBio has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500.

Earnings and Valuation

This table compares AnaptysBio and Axsome Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnaptysBio$8 million73.58$-97,340,000.00($3.60)-5.98
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-27.24

Axsome Therapeutics has lower revenue, but higher earnings than AnaptysBio. Axsome Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Summary

Axsome Therapeutics beats AnaptysBio on 8 of the 12 factors compared between the two stocks.

AnaptysBio (NASDAQ:ANAB) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Insider and Institutional Ownership

94.3% of Seres Therapeutics shares are owned by institutional investors. 13.0% of AnaptysBio shares are owned by company insiders. Comparatively, 4.8% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for AnaptysBio and Seres Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AnaptysBio13302.29
Seres Therapeutics01602.86

AnaptysBio currently has a consensus target price of $30.2857, indicating a potential upside of 41.59%. Seres Therapeutics has a consensus target price of $38.1667, indicating a potential upside of 76.94%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than AnaptysBio.

Profitability

This table compares AnaptysBio and Seres Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AnaptysBioN/A-19.09%-17.94%
Seres Therapeutics-385.22%-2,867.98%-51.24%

Volatility & Risk

AnaptysBio has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 4.07, suggesting that its share price is 307% more volatile than the S&P 500.

Earnings and Valuation

This table compares AnaptysBio and Seres Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnaptysBio$8 million73.58$-97,340,000.00($3.60)-5.98
Seres Therapeutics$34.51 million57.57$-70,280,000.00($1.20)-18.08

Seres Therapeutics has higher revenue and earnings than AnaptysBio. Seres Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Summary

Seres Therapeutics beats AnaptysBio on 8 of the 14 factors compared between the two stocks.


AnaptysBio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.16+0.3%$2.20 billion$963.01 million13.71News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$28.01+4.2%$2.05 billion$23.90 million-17.40Analyst Report
Analyst Revision
News Coverage
Amarin logo
AMRN
Amarin
1.6$5.24+3.1%$2.00 billion$429.76 million-104.78News Coverage
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.74+3.3%$1.98 billion$410,000.00-6.25Analyst Report
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$54.75+5.6%$1.93 billionN/A-20.35
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$21.70+3.2%$1.92 billion$34.51 million-18.55
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$65.50+4.9%$1.91 billionN/A-27.87Increase in Short Interest
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$48.06+5.0%$1.87 billionN/A0.00Analyst Report
Gap Down
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.28+3.4%$1.87 billion$103.54 million-19.01Insider Selling
MORF
Morphic
1.1$58.01+0.6%$1.87 billion$16.98 million-37.19Insider Selling
Decrease in Short Interest
News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$121.26+4.7%$1.85 billionN/A-10.95
Kura Oncology logo
KURA
Kura Oncology
1.6$29.14+5.6%$1.82 billionN/A-17.88Gap Down
FibroGen logo
FGEN
FibroGen
1.8$19.68+0.3%$1.81 billion$256.58 million-7.54Analyst Report
News Coverage
MacroGenics logo
MGNX
MacroGenics
1.2$31.67+6.6%$1.77 billion$64.19 million-10.12Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.98+0.1%$1.77 billion$14.87 million-14.17Increase in Short Interest
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.84+1.4%$1.73 billion$1.63 billion14.24Analyst Report
Decrease in Short Interest
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.41+2.0%$1.71 billion$26.87 million-12.78Insider Selling
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.60+2.7%$1.66 billion$428.41 million15.36News Coverage
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.5$32.02+2.3%$1.66 billion$392.76 million13.29Analyst Upgrade
Analyst Revision
News Coverage
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.79+0.0%$1.63 billion$320,000.00-8.70Analyst Report
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.90+1.5%$1.62 billionN/A0.00Analyst Revision
uniQure logo
QURE
uniQure
1.7$34.92+0.1%$1.57 billion$7.28 million-9.26
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$24.97+9.0%$1.57 billion$2.34 million-10.58Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$17.97+5.0%$1.55 billionN/A-6.40Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.36+4.0%$1.52 billion$145.97 million-7.03Gap Down
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$25.91+3.4%$1.51 billion$175.34 million-15.24Analyst Report
Analyst Revision
News Coverage
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.5$35.71+9.1%$1.51 billionN/A0.00Analyst Upgrade
Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.4$61.76+3.7%$1.49 billionN/A0.00Increase in Short Interest
Gap Down
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.53+0.6%$1.47 billionN/A0.00Insider Selling
Increase in Short Interest
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.66+5.1%$1.45 billion$82.27 million-18.68
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$36.30+0.7%$1.44 billionN/A-151.25Gap Down
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$42.45+4.2%$1.43 billionN/A0.00Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$26.85+5.4%$1.43 billionN/A0.00Increase in Short Interest
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.79+2.1%$1.42 billion$6.20 million-14.38
ATBPD
Antibe Therapeutics
0.1$3.66+0.0%$1.42 billion$7.51 million-6.10Gap Down
Endo International logo
ENDP
Endo International
1.3$6.29+2.9%$1.41 billion$2.91 billion-9.25
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$28.45+2.2%$1.39 billionN/A-3.08Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.17+2.4%$1.37 billion$19.89 million-13.29
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.78+4.8%$1.37 billion$4.23 million-20.58Increase in Short Interest
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.45+4.1%$1.34 billion$73.41 million-4.53Unusual Options Activity
News Coverage
Gap Down
Shattuck Labs logo
STTK
Shattuck Labs
1.5$33.12+3.0%$1.34 billionN/A0.00Analyst Report
Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$36.28+0.2%$1.33 billionN/A0.00Analyst Upgrade
OLMA
Olema Pharmaceuticals
1.6$34.18+5.0%$1.30 billionN/A0.00Increase in Short Interest
Zymeworks logo
ZYME
Zymeworks
1.8$30.70+9.1%$1.29 billion$29.54 million-8.14News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$23.12+1.0%$1.28 billionN/A0.00Insider Selling
Unusual Options Activity
Gap Down
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$39.45+1.2%$1.22 billionN/A-2.82Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.53+4.3%$1.21 billionN/A-19.18
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.81+5.5%$1.21 billion$4.23 million-9.39News Coverage
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$34.50+6.0%$1.20 billionN/A0.00
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.